2023
TP53-mediated clonal hematopoiesis confers increased risk for incident atherosclerotic disease
Zekavat S, Viana-Huete V, Matesanz N, Jorshery S, Zuriaga M, Uddin M, Trinder M, Paruchuri K, Zorita V, Ferrer-Pérez A, Amorós-Pérez M, Kunderfranco P, Carriero R, Greco C, Aroca-Crevillen A, Hidalgo A, Damrauer S, Ballantyne C, Niroula A, Gibson C, Pirruccello J, Griffin G, Ebert B, Libby P, Fuster V, Zhao H, Ghassemi M, Natarajan P, Bick A, Fuster J, Klarin D. TP53-mediated clonal hematopoiesis confers increased risk for incident atherosclerotic disease. Nature Cardiovascular Research 2023, 2: 144-158. PMID: 36949957, PMCID: PMC10026701, DOI: 10.1038/s44161-022-00206-6.Peer-Reviewed Original ResearchPeripheral artery diseaseIncident peripheral artery diseaseArtery diseaseAtherosclerotic diseaseChimeric miceIncident atherosclerotic diseaseCoronary artery diseaseAortic plaque sizeAccumulation of macrophagesMass General Brigham BiobankEntire arterial systemWhole-exome sequencingDNA damage repair genesCause mortalityCoronary arteryHematologic malignanciesPlaque macrophagesClinical dataTransplantation strategiesArterial systemPlaque sizeAtherosclerosisClonal hematopoiesisDiseaseIndeterminate potential
2017
Genetic Dissection of the Impact of miR-33a and miR-33b during the Progression of Atherosclerosis
Price NL, Rotllan N, Canfrán-Duque A, Zhang X, Pati P, Arias N, Moen J, Mayr M, Ford DA, Baldán Á, Suárez Y, Fernández-Hernando C. Genetic Dissection of the Impact of miR-33a and miR-33b during the Progression of Atherosclerosis. Cell Reports 2017, 21: 1317-1330. PMID: 29091769, PMCID: PMC5687841, DOI: 10.1016/j.celrep.2017.10.023.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAortaAtherosclerosisATP Binding Cassette Transporter 1Blood GlucoseCells, CulturedCholesterolCholesterol, HDLDisease ProgressionGene Regulatory NetworksMacrophages, PeritonealMaleMiceMice, Inbred C57BLMice, KnockoutMicroRNAsMitochondrial Trifunctional Protein, beta SubunitMyocardiumReceptors, LDLConceptsPlaque burdenMiR-33MiR-33-deficient miceReduced plaque burdenProgression of atherosclerosisPro-atherogenic effectsMacrophage cholesterol effluxDecreases lipid accumulationTreatment of atherosclerosisMacrophage-specific lossMiR-33 deficiencyPromotes obesityHDL levelsInsulin resistancePlaque macrophagesProtective effectHyperlipidemic conditionsCholesterol effluxPlaque developmentLipid metabolismAtherosclerosisLipid accumulationHDL biogenesisPromising targetMacrophages
2016
In Vivo PET Imaging of HDL in Multiple Atherosclerosis Models
Pérez-Medina C, Binderup T, Lobatto ME, Tang J, Calcagno C, Giesen L, Wessel CH, Witjes J, Ishino S, Baxter S, Zhao Y, Ramachandran S, Eldib M, Sánchez-Gaytán BL, Robson PM, Bini J, Granada JF, Fish KM, Stroes ES, Duivenvoorden R, Tsimikas S, Lewis JS, Reiner T, Fuster V, Kjær A, Fisher EA, Fayad ZA, Mulder WJ. In Vivo PET Imaging of HDL in Multiple Atherosclerosis Models. JACC Cardiovascular Imaging 2016, 9: 950-961. PMID: 27236528, PMCID: PMC5589956, DOI: 10.1016/j.jcmg.2016.01.020.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAortaAortic DiseasesApolipoproteins EAtherosclerosisAutoradiographyDisease Models, AnimalFemaleFlow CytometryLipoproteins, HDLMagnetic Resonance ImagingMaleMice, Inbred C57BLMice, KnockoutMolecular ImagingOptical ImagingPlaque, AtheroscleroticPositron Emission Tomography Computed TomographyPredictive Value of TestsRabbitsRadioisotopesRadiopharmaceuticalsReproducibility of ResultsTissue DistributionZirconiumConceptsHigh-density lipoproteinPositron emission tomographyHDL nanoparticlesPlaque macrophagesPET imagingAtherosclerotic plaque macrophagesRadioactivity uptake valuesIncident cardiovascular eventsCoronary heart diseaseDistinct pharmacokinetic profileStrong independent predictorHDL cholesterol concentrationsReverse cholesterol transportAdvanced atherosclerotic lesionsAccumulation of radioactivityMagnetic resonance imagingVivo PET imagingNoninvasive imaging toolNoninvasive PET imagingCardiovascular eventsIndependent predictorsAtherosclerosis modelHeart diseaseMurine modelAtherosclerotic lesions
2011
Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis
Rayner KJ, Sheedy FJ, Esau CC, Hussain FN, Temel RE, Parathath S, van Gils JM, Rayner AJ, Chang AN, Suarez Y, Fernandez-Hernando C, Fisher EA, Moore KJ. Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. Journal Of Clinical Investigation 2011, 121: 2921-2931. PMID: 21646721, PMCID: PMC3223840, DOI: 10.1172/jci57275.Peer-Reviewed Original ResearchConceptsABC transporter A1HDL levelsRegression of atherosclerosisCholesterol transportMiR-33MiR-33 inhibitionAtherosclerotic vascular diseasePlasma HDL levelsInflammatory gene expressionReverse cholesterol transportABCA1 levelsAtherosclerosis regressionVascular diseasePlaque macrophagesPlaque stabilityABCA1 expressionAtherosclerotic plaquesMice promotesProtective roleLipid metabolismLDL receptorClinical therapyPlaque sizeAtherosclerosisSREBF2 gene
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply